Literature DB >> 16220012

Primary thyroid malignancies in Tehran, Iran.

Bagher Larijani1, Mohammad Ali Mohagheghi, Mohammad Hassan Bastanhagh, Ali Reza Mosavi-Jarrahi, Vahid Haghpanah, Seyed Mohammad Tavangar, Fatemeh Bandarian, Nasim Khaleghian.   

Abstract

OBJECTIVE: The aim of this study was to present a descriptive epidemiology of primary thyroid cancer in Tehran, Iran, using cancer registry data. SUBJECTS AND METHODS: All cases of thyroid cancer registered from 1998 to 2001 in Tehran Metropolitan Area Population-Based Cancer Registry were used for this study. The incidence of thyroid cancer was estimated for the area covered by the cancer registry. Survival of patients was ascertained by telephone call to the patients or the patient's family and/or linkage of registry data to mortality data from the Bureau of Vital Statistics. Patient's survival was based on sex, age and morphological type of tumour.
RESULTS: Four hundred and twenty-nine cases of primary thyroid cancer were registered in the Tehran Metropolitan Area Cancer Registry. The incidence of thyroid cancer was 3.5 and 1.0 per 100,000 population per year for females and males, respectively. Seventy percent of tumours were papillary, 11% follicular, 6.2% medullary, and the rest were other subtypes. The papillary and follicular variants occurred in younger age: 43 +/- 16 and 46 +/- 13 years, respectively; the medullary and anaplastic variants occurred in older age: over 50 years. A 5-year survival rate was 82.2%, with median survival of 66 months and 95% confidence interval of 63 and 69 months. Men and women had a similar survival experience.
CONCLUSIONS: While the incidence of thyroid cancer was slightly high, the descriptive epidemiology of thyroid cancer in Tehran did not manifest a unique feature. Tehran patients experienced a high rate of survival, and the survival time for males and females was similar. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 16220012     DOI: 10.1159/000088112

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  15 in total

Review 1.  The Prevalence of Thyroid Cancer in Iran: a Systematic Review and Meta-analysis.

Authors:  Nader Salari; Mohsen Kazeminia; Masoud Mohammadi
Journal:  Indian J Surg Oncol       Date:  2021-11-12

Review 2.  Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.

Authors:  Mohammad-Reza Mahmoudian-Sani; Ameneh Mehri-Ghahfarrokhi; Majid Asadi-Samani; Gholam-Reza Mobini
Journal:  Eur Thyroid J       Date:  2017-04-07

3.  Inequalities in cancer distribution in tehran; a disaggregated estimation of 2007 incidencea by 22 districts.

Authors:  Marzieh Rohani Rasaf; Rashid Ramezani; Mitra Mehrazma; Mohamad Reza Rohani Rasaf; Mohsen Asadi-Lari
Journal:  Int J Prev Med       Date:  2012-07

4.  Recent Trends and Geographical Distribution of Thyroid Cancer in Iran from 2004 to 2009.

Authors:  Ali Safavi; Rozita Jafari; Samira Chaibakhsh; Rashid Ramezani-Daryasar; Mansour Rezaei; Amir Ali Safavi
Journal:  Iran J Cancer Prev       Date:  2014

5.  Survival of Patients with Thyroid Cancer in Yazd, Iran

Authors:  Hassan Ali Vahedian Ardakani; Mansour Moghimi; Mohammad Shayestehpour; Masoud Doosti; Shamsi Beigi Sharifabadi
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

6.  Genetic and Epigenetic of Medullary Thyroid Cancer

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran Biomed J       Date:  2017-11-11

Review 7.  Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran J Pathol       Date:  2017-07-01

Review 8.  Oncometabolites as biomarkers in thyroid cancer: a systematic review.

Authors:  Fatemeh Khatami; Moloud Payab; Masoumeh Sarvari; Kambiz Gilany; Bagher Larijani; Babak Arjmand; Seyed Mohammad Tavangar
Journal:  Cancer Manag Res       Date:  2019-02-25       Impact factor: 3.989

Review 9.  Personalized treatment options for thyroid cancer: current perspectives.

Authors:  Fatemeh Khatami; Bagher Larijani; Shekoufeh Nikfar; Mandana Hasanzad; Kiarad Fendereski; Seyed Mohammad Tavangar
Journal:  Pharmgenomics Pers Med       Date:  2019-09-13

Review 10.  Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Biomark Insights       Date:  2018-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.